Arcus Biosciences' President Juan Jaen Sells Shares
Juan Jaen sold 9,236 shares of Arcus Biosciences, valued at $249,649.08.
Key Points
- Juan Jaen, President of Arcus Biosciences, sold 9,236 shares for $249,649.08 on June 22, 2026.
- Shares of Arcus Biosciences traded near $29.05 with a market cap of $3.42 billion and a forward P/E ratio of -8.78.
- Analysts have set price targets for Arcus ranging from $22 to $49, with a consensus rating of 'strong buy'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Juan Jaen, the President of Arcus Biosciences, Inc. (NYSE: RCUS), recently sold 9,236 shares of the company. The transaction, valued at $249,649.08, took place on June 22, 2026, at an average price of $27.03 per share. This sale was part of a pre-planned trading arrangement.
Insider Buying and Selling at Arcus Biosciences, Inc.
Juan Jaen has been active in the market recently, with multiple sales including 6,431 shares at $29.66 on June 24, and 15,764 shares at $27.73 on June 23, all as part of planned transactions. Additionally, Yasunori Kaneko purchased 16,900 shares on June 11, while Carolyn Tang, the General Counsel, sold and bought 34,090 shares on the same day.
Arcus Biosciences, Inc. Stock Down 0.5%
Shares of NYSE:RCUS traded near $29.05 on Thursday. Arcus Biosciences has a market cap of approximately $3.42 billion and a forward P/E ratio of -8.78, indicating it is not currently profitable. The stock's 52-week range spans from $7.91 to $28.72. It has a 50-day moving average of $24.26 and a 200-day moving average of $20.95. The company maintains a healthy current ratio of 4.04 and a quick ratio of 3.97, with a debt-to-equity ratio of 21.56.
$RCUS stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been active in re-evaluating Arcus Biosciences. On June 4, 2026, LifeSci Capital initiated coverage with a 'buy' rating and a $46 price target. Truist Securities assumed coverage with a 'buy' rating and a $35 target on May 18. Morgan Stanley maintained a 'hold' rating with a $22 target on May 11. The consensus among 12 analysts is a 'strong buy' with a mean target price of $35.75.
About Arcus Biosciences
Arcus Biosciences, Inc., headquartered in Hayward, California, is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies. The company has a diverse portfolio of products in various stages of clinical trials, including treatments for kidney, lung, and gastrointestinal cancers. Partnerships with major companies like AstraZeneca and Bristol-Myers Squibb support its research and development efforts. Led by CEO Dr. Terry J. Rosen, the company employs 601 people.
Bottom Line
Arcus Biosciences continues to be a focus for investors, with insider sales and analyst ratings highlighting its market activities. Juan Jaen's recent share sales were planned, suggesting strategic financial management. Investors should note that 13F filings and insider transactions are historical and may not reflect current positions.
Get Arcus Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RCUS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.